DE60213810D1 - Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel - Google Patents

Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel

Info

Publication number
DE60213810D1
DE60213810D1 DE60213810T DE60213810T DE60213810D1 DE 60213810 D1 DE60213810 D1 DE 60213810D1 DE 60213810 T DE60213810 T DE 60213810T DE 60213810 T DE60213810 T DE 60213810T DE 60213810 D1 DE60213810 D1 DE 60213810D1
Authority
DE
Germany
Prior art keywords
benzidides
sulphonamides
sulfonyl
benzoyl
antitumor agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60213810T
Other languages
English (en)
Other versions
DE60213810T2 (de
Inventor
Hughes Corbett
Sue Grossman
Lynn Lobb
Chuan Shih
Arthur Hipskind
Ho-Shen Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60213810D1 publication Critical patent/DE60213810D1/de
Application granted granted Critical
Publication of DE60213810T2 publication Critical patent/DE60213810T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • C07D213/34Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
DE60213810T 2001-06-06 2002-05-24 Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel Expired - Fee Related DE60213810T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06
US296350P 2001-06-06
PCT/US2002/015142 WO2002098848A1 (en) 2001-06-06 2002-05-24 Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents

Publications (2)

Publication Number Publication Date
DE60213810D1 true DE60213810D1 (de) 2006-09-21
DE60213810T2 DE60213810T2 (de) 2007-02-01

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213810T Expired - Fee Related DE60213810T2 (de) 2001-06-06 2002-05-24 Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel

Country Status (36)

Country Link
US (1) US7183320B2 (de)
EP (1) EP1401806B1 (de)
JP (1) JP4167173B2 (de)
KR (1) KR100880760B1 (de)
CN (1) CN100475787C (de)
AR (1) AR036079A1 (de)
AT (1) ATE335722T1 (de)
AU (1) AU2002259204B2 (de)
BR (1) BR0210078A (de)
CA (1) CA2446719A1 (de)
CR (1) CR7182A (de)
CY (1) CY1105386T1 (de)
CZ (1) CZ20033296A3 (de)
DE (1) DE60213810T2 (de)
DK (1) DK1401806T3 (de)
EA (1) EA005810B1 (de)
EC (1) ECSP034874A (de)
EG (1) EG24356A (de)
ES (1) ES2269688T3 (de)
HK (1) HK1064360A1 (de)
HR (1) HRP20031000A2 (de)
HU (1) HUP0400114A3 (de)
IL (1) IL158985A0 (de)
MX (1) MXPA03011197A (de)
MY (1) MY136855A (de)
NO (1) NO20035366L (de)
NZ (1) NZ529098A (de)
PE (1) PE20030199A1 (de)
PL (1) PL367188A1 (de)
PT (1) PT1401806E (de)
SK (1) SK14642003A3 (de)
SV (1) SV2003001076A (de)
TW (1) TWI266761B (de)
UA (1) UA74889C2 (de)
WO (1) WO2002098848A1 (de)
ZA (1) ZA200308644B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316984T2 (de) 2002-11-22 2008-07-17 Eli Lilly And Co., Indianapolis Benzoylsulfonamide als antitumor-mittel
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
ATE542796T1 (de) * 2004-05-26 2012-02-15 Abbott Lab N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030947A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
ME01222B (me) 2005-02-28 2013-06-20 Eisai R&D Man Co Ltd Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
KR20070114774A (ko) * 2005-02-28 2007-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 혈관 신생 저해 물질과의 신규 병용
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
EP2015070A4 (de) 2006-04-20 2010-04-21 Eisai R&D Man Co Ltd Neuer marker für empfindlichkeit gegenüber einer sulfonamidverbindung
CN101534904B (zh) 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
US7879884B2 (en) 2007-05-16 2011-02-01 Hoffmann-La Roche Inc. Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
JP5613176B2 (ja) * 2009-01-19 2014-10-22 アッヴィ・インコーポレイテッド 癌並びに免疫及び自己免疫疾患の治療用アポトーシス誘導剤
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
KR200457823Y1 (ko) * 2009-05-08 2012-01-05 황정용 쭈꾸미 포획용 어구
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20190086591A (ko) 2009-05-26 2019-07-22 애브비 아일랜드 언리미티드 컴퍼니 암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2550258T3 (en) * 2010-03-25 2015-12-07 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR102095698B1 (ko) 2010-10-29 2020-04-01 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
HUE031267T2 (en) 2010-11-23 2017-06-28 Abbvie Ireland Unlimited Co Methods of treatment using selective BCL-2 inhibitors
EP2643322B1 (de) 2010-11-23 2017-08-30 Abbvie Inc. Salze und kristalline formen eines apoptoseauslösers
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (zh) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 一种取代的磺酰胺基(硫代)羰基化合物及其用途
AU2016216782C1 (en) 2015-02-13 2021-02-18 Oxford Drug Design Limited Novel N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors
CN105753748B (zh) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 一种医药中间体磺酰类化合物的合成方法
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
WO2018237163A1 (en) * 2017-06-23 2018-12-27 Roman Manetsch 5-AMINOLEVULINATE SYNTHASE INHIBITORS AND METHODS OF USE
EP3731839A4 (de) * 2017-12-29 2021-11-10 Gongwin Biopharm Co., Ltd. (Taiwan) Benzolsulfonamidderivate und verfahren zur modulierung von lipid-rafts
CN114790149A (zh) * 2021-01-26 2022-07-26 江苏中旗科技股份有限公司 一种以2-氯-4-氟苯胺为原料合成2-氯-4-氟苯甲酸的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
JP2679498B2 (ja) * 1991-12-25 1997-11-19 王子製紙株式会社 感熱記録体
CA2110524A1 (en) * 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
ATE230275T1 (de) * 1995-10-25 2003-01-15 Senju Pharma Co Angiogense-inhibitor
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
CA2362917C (en) * 1999-02-12 2003-08-05 Cellpath, Inc. Methods for anti-tumor therapy
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters

Also Published As

Publication number Publication date
AU2002259204B2 (en) 2008-01-17
IL158985A0 (en) 2004-05-12
CN1514824A (zh) 2004-07-21
HRP20031000A2 (en) 2004-04-30
CA2446719A1 (en) 2002-12-12
KR100880760B1 (ko) 2009-02-02
CN100475787C (zh) 2009-04-08
MXPA03011197A (es) 2004-02-26
EA200400006A1 (ru) 2004-06-24
UA74889C2 (en) 2006-02-15
PE20030199A1 (es) 2003-03-12
JP4167173B2 (ja) 2008-10-15
ATE335722T1 (de) 2006-09-15
AR036079A1 (es) 2004-08-11
TWI266761B (en) 2006-11-21
KR20040007656A (ko) 2004-01-24
SV2003001076A (es) 2003-07-29
PT1401806E (pt) 2006-11-30
EG24356A (en) 2009-03-04
US7183320B2 (en) 2007-02-27
EP1401806B1 (de) 2006-08-09
NZ529098A (en) 2005-08-26
HUP0400114A2 (hu) 2005-04-28
HUP0400114A3 (en) 2007-05-02
CZ20033296A3 (cs) 2004-04-14
ZA200308644B (en) 2005-02-07
HK1064360A1 (en) 2005-01-28
NO20035366D0 (no) 2003-12-02
MY136855A (en) 2008-11-28
DK1401806T3 (da) 2006-11-27
US20040157741A1 (en) 2004-08-12
CY1105386T1 (el) 2010-04-28
DE60213810T2 (de) 2007-02-01
ES2269688T3 (es) 2007-04-01
EA005810B1 (ru) 2005-06-30
JP2004530709A (ja) 2004-10-07
WO2002098848A1 (en) 2002-12-12
EP1401806A1 (de) 2004-03-31
SK14642003A3 (sk) 2004-12-01
NO20035366L (no) 2004-02-06
CR7182A (es) 2004-06-08
BR0210078A (pt) 2004-06-22
PL367188A1 (en) 2005-02-21
ECSP034874A (es) 2004-01-28

Similar Documents

Publication Publication Date Title
DE60213810D1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
DE60228608D1 (de) Tintenrezepturen und verwendung derselben
ATE359792T1 (de) Harnstofe von 2-aminobenzothiazolen als adenosin- modulatoren
DE50115561D1 (de) Spektralphotometer und Verwendung desselben
DE60218695D1 (de) Biosensoren und messverfahren
IS2497B (is) Ný sýklóhexýl súlfon
DE50206392D1 (de) Elektrochirurgisches instrument
DE60319330D1 (de) Chirurgisches Instrument
DE50212455D1 (de) Verwendung von Dimerdiolen
DE60226581D1 (de) Anzeigeeinheit und ansteuerverfahren dafür
ATE459598T1 (de) Sulfonamidderivate
DE60214314D1 (de) Optometrisches Instrument
DE60221059D1 (de) Armaturenbrettrahmen
DE60230162D1 (de) Polymerisate und ihre verwendung
DE60323517D1 (de) Hybridisierungsnachweisverfahren und bioassay-vorr
DE60334091D1 (de) Flammhemmendes mischgewebe
BR0206044B1 (pt) Composição alvejante
DE60210926D1 (de) Antikrebs-heilmittel welche substituierte pyrrole und paclitaxel enthält
DE50300769D1 (de) Erdalkalialuminosilicatglas und verwendung
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
ATE431144T1 (de) Neue formulierungen und ihre verwendung
DE60208365D1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
FR2823830B1 (fr) Plot lumineux
ATE400292T1 (de) Verwendung von leptin bei unfruchtbarkeit
DE60215217D1 (de) Substituierte arylcycloalkane und deren verwendung als antikrebsmittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee